As drug trends and diagnostic technologies evolve, toxicology must adapt to meet the demands of healthcare, workplace safety, and public health—focusing on opioid detection, CBD use, patient-centered testing, and new methods like saliva analysis, each bringing distinct challenges and opportunities. The following podcast episodes feature chemistry-related interviews that discuss these topics.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, for a timely discussion on tick-borne diseases.

Register now – Oct. 14, 2025 - PACE/State of FL - This webinar will provide an overview of recent regulatory changes impacting clinical laboratories. This will include the latest updates to Clinical Laboratory Improvement Amendments (CLIA) memos and brochures, the termination of Clinical Laboratory Improvement Advisory Committee (CLIAC) and its impact to clinical laboratories, a summary of the FDA LDT final rule regulatory journey, and a discussion of the shift to announced inspections.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joined the “Medical Alley” podcast to discuss innovation in diagnostics.

In October 2022, Mayo Clinic Laboratories announced thirty new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss how traveling and gathering impacts respiratory virus spread, and how testing and lab stewardship will be critical in the months ahead. They also highlight Dr. Pritt’s parasitology blog, Creepy Dreadful Wonderful Parasites, which just posted its 700th case.

As an event management coordinator for the Department of Laboratory Medicine and Pathology at Mayo Clinic, Jason Majorowicz acts as an investigator when something may deviate from its established process. With a background in biotechnology and over 20 years of experience at Mayo Clinic, Jason helps with process improvement, quality assurance, and problem-solving.

This list includes updates posted to mayocliniclabs.com during the month of October.

In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.

This week's research roundup features: Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations

In the inaugural episode of the "Leveraging the Laboratory" podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by outreach colleagues Brianne Newton and Ellen Dijkman Dulkes. They discuss their laboratory backgrounds, the history and importance of laboratory outreach, and how their work can support the growth of hospital laboratories.

Topic highlights include: Minnesota Department of Health sees jump in RSV hospitalizations, Vaccine booster, COVID-19 levels remain low in Minnesota, CDC discussing using oral polio vaccine to combat New York outbreak: report

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

Jason Hipp, M.D., Ph.D., chair of Computational Pathology and AI at Mayo Clinic’s Department of Laboratory Medicine and Pathology, and director of Digital Innovation for Mayo Clinic Laboratories, spoke with the Dark Report about how Mayo Clinic is modernizing clinical pathology workflows and how other labs can apply those lessons in their organizations.

Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.